Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2

Leukemia

Volumn 26, Issue 11, 2012, Pages 2343-2352

  Rosato, P ^a   Anastasiadou, E ^a   Garg, N ^b   Lenze, D ^c   Boccellato, F ^a   Vincenti, S ^d   Severa, M ^e   Coccia, E M ^e   Bigi, R ^a   Cirone, M ^a   Ferretti, E ^b   Campese, A F ^b   Hummel, M ^c   Frati, L ^a   Presutti, C ^d   Faggioni, A ^a   Trivedi, P ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

DLBCL; EBNA2; EBV; microRNA; miR 146a; miR 21

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 2; INTERFERON; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MICRORNA 146A; MICRORNA 21; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; EPSTEIN BARR VIRUS; LYMPHOCYTE TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE KNOCKDOWN TECHNIQUES; HERPESVIRUS 4, HUMAN; HUMANS; MICRORNAS; VIRAL PROTEINS;

EID: 84869094689     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.108     Document Type: Article

References (50)

1. Rowe M, Kelly GL, Bell AI, Rickinson AB. Burkitt's lymphoma: The Rosetta Stone deciphering Epstein-Barr virus biology. Semin Cancer Biol 2009; 19: 377-388.
2. Rabson M, Gradoville L, Heston L, Miller G. Non-immortalizing P3J-HR-1 Epstein-Barr virus: A deletion mutant of its transforming parent, Jijoye. J Virol 1982; 44: 834-844. (Pubitemid 13250545)
3. Marchini A, Kieff E, Longnecker R. Marker rescue of a transformation-negative Epstein-Barr virus recombinant from an infected Burkitt lymphoma cell line: A method useful for analysis of genes essential for transformation. J Virol 1993; 67: 606-609. (Pubitemid 23003031)
4. Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, Kempkes B. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: Implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. EMBO J 1996; 15: 375-382.
5. Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol 2007; 60: 1397-1402. (Pubitemid 350247257)
6. Grossman SR, Johannsen E, Tong X, Yalamanchili R, Kieff E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci USA 1994; 91: 7568-7572.
7. Laux G, Dugrillon F, Eckert C, Adam B, Zimber-Strobl U, Bornkamm GW. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol 1994; 68: 6947-6958. (Pubitemid 24328744)
8. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol 1995; 69: 253-262. (Pubitemid 24378801)
9. Wang L, Grossman SR, Kieff E. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc Natl Acad Sci USA 2000; 97: 430-435. (Pubitemid 30055848)
10. Lucchesi W, Brady G, Dittrich-Breiholz O, Kracht M, Russ R, Farrell PJ. Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol 2008; 82: 7456-7466. (Pubitemid 352031213)
11. Boccellato F, Anastasiadou E, Rosato P, Kempkes B, Frati L, Faggioni A et al. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells. J Virol 2007; 81: 2274-2283.
12. Zhao B, Maruo S, Cooper AR, Chase M, Johannsen E, Kieff E et al. RNAs induced by Epstein-Barr virus nuclear antigen 2 in lymphoblastoid cell lines. Proc Natl Acad Sci USA 2006; 103: 1900-1905. (Pubitemid 43228790)
13. Calin GA, Croce CM. Chromosomal rearrangements and microRNAs: A new cancer link with clinical implications. J Clin Invest 2007; 117: 2059-2066. (Pubitemid 47219545)
14. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J et al. Identification of virus-encoded microRNAs. Science 2004; 304: 734-736. (Pubitemid 38560879)
15. Kluiver J, van den Berg A, de Jong D, Blokzijl T, Harms G, Bouwman E et al. Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene 2007; 26: 3769-3776. (Pubitemid 46878126)
16. Kluiver J, Haralambieva E, de Jong D, Blokzijl T, Jacobs S, Kroesen BJ et al. Lack of BIC and microRNA miR-155 expression in primary cases of Burkitt lymphoma. Genes Chromosomes Cancer 2006; 45: 147-153. (Pubitemid 43191021)
17. Lu F, Weidmer A, Liu CG, Volinia S, Croce CM, Lieberman PM. Epstein-Barr virusinduced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. J Virol 2008; 82: 10436-10443. (Pubitemid 352691173)
18. Cameron JE, Yin Q, Fewell C, Lacey M, McBride J, Wang X et al. The Epstein-Barr Virus latent membrane protein 1 (LMP1) induces cellular microRNA-146a, a modulator of lymphocyte signaling pathways. J Virol 2008; 82: 1946-1958. (Pubitemid 351206940)
19. Motsch N, Pfuhl T, Mrazek J, Barth S, Grasser FA. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a. RNA Biol 2007; 4: 131-137. (Pubitemid 351237914)
20. Anastasiadou E, Boccellato F, Vincenti S, Rosato P, Bozzoni I, Frati L et al. Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. Oncogene 2010; 29: 1316-1328.
21. Shimakage M, Kurata A, Inoue H, Okamoto Y, Yutsudo M, Hakura A. Tumorigenicity of EBNA2-transfected cells. FEBS Lett 1995; 371: 245-248.
22. Pan SH, Tai CC, Lin CS, Hsu WB, Chou SF, Lai CC et al. Epstein-Barr virus nuclear antigen 2 disrupts mitotic checkpoint and causes chromosomal instability. Carcinogenesis 2009; 30: 366-375.
23. Tornell J, Farzad S, EspanDer-Jansson A, Matejka G, Isaksson O, Rymo L. Expression of Epstein-Barr nuclear antigen 2 in kidney tubule cells induce tumors in transgenic mice. Oncogene 1996; 12: 1521-1528. (Pubitemid 26132039)
24. Amini RM, Berglund M, Rosenquist R, Von Heideman A, Lagercrantz S, Thunberg U et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma 2002; 43: 2179-2189. (Pubitemid 35189521)
25. Trivedi P, Zhang QJ, Chen F, Minarovits J, Ekman M, Biberfeld P et al. Parallel existence of Epstein-Barr virus (EBV) positive and negative cells in a sporadic case of Burkitt lymphoma. Oncogene 1995; 113: 505-510.
26. Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, Delecluse HJ et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J 1995; 14: 88-96.
27. Maruo S, Yang L, Takada K. Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J Gen Virol 2001; 82: 2373-2383. (Pubitemid 32936771)
28. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 2006; 103: 12481-12486. (Pubitemid 44267285)
29. Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, Iwamoto K et al. Aberrant overexpression of microRNAs activate AKT signaling via downregulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 2009; 114: 3265-3275.
30. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983-10985. (Pubitemid 32928669)
31. Godshalk S, Bhaduri-McIntosh ES, Slack FJ. Epstein-Barr virus-mediated dysregulation of human microRNA expression. Cell Cycle 2008; 7: 3595-3600.
32. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-6033. (Pubitemid 40994386)
33. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261. (Pubitemid 43271657)
34. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, Wei WI. Mature miR-184 as Potential Oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008; 14: 2588-2592.
35. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S et al. MicroRNA gene expression Deregulation in human breast cancer. Cancer Res 2005; 65: 7065-7070. (Pubitemid 41161233)
36. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109: 4944-4951. (Pubitemid 46827793)
37. Medina PP, Nolde M, Slack FJ. Oncomir addiction in an in vivo model of microRNa-21 induced pre-B cell lymphoma. Nature 2010; 467: 86-90.
38. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803. (Pubitemid 46663837)
39. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumorsuppressor genes in invasion and metastasis. Cell Res 2008; 18: 350-359. (Pubitemid 351333899)
40. Cameron JE, Fewell C, Yin Q, McBride J, Wang X, Lin Z et al. Epstein-Barr virus growth/latency III program alters cellular microRNA expression. Virology 2008b; 382: 257-266.
41. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136. (Pubitemid 351485639)
42. Baek D, Villon J, Shin C, Camargo FD, Gygi SP, Bartel DP 2008The impact of microRNAs on protein output. Nature 455: 64-71.
43. Masucci MG, Torsteindottir S, Colombani J, Brautbar C, Klein E, Klein G. Downregulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci USA 1987; 84: 4567-4571. (Pubitemid 17097854)
44. Hou J, Wang P, Lin L, Liu X, Ma F, An H et al. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J Immunol 2009; 183: 2150-2158.
45. Tang Y, Luo X, Cui H, Ni X, Yuan M, Guo Y et al. MicroRNA-146A contributes to a normal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065-1075.
46. Kanda K, Kempkes B, Bornkamm GW, Von Gabain A, Decker T. The Epstein-Barr virus nuclear antigen 2 (EBNA2), a protein required for B lymphocyte immortalization, induces the synthesis of type I interferon in Burkitt's lymphomacell lines. Biol Chem 1999; 380: 213-221. (Pubitemid 29118843)
47. Hiscott J, Wong A, Alper D, Xanthoudakis S. Transactivation of type 1 interferon promoters by simian virus 40 T antigen. Mol Cell Biol 1988; 8: 3397-3405.
48. Nielsch U, Pine R, Zimmer SG, Babiss LE. Induced expression of the endogenous beta interferon gene in adenovirus type 5-transformed rat fibroblasts. J Virol 1992; 66: 1884-1890.
49. Kanda K, Decker T, Aman P, Wahlstrom M, Von Gabain A, Kallin B. The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Mol Cell Biol 1992; 12: 4930-4936.
50. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kB actitivity with redution of metastatic potential in breast cancer cells. Oncogene 2008; 27: 5643-5647.